Rituximab (anti-CD20 monoclonal antibody) in lymphoproliferative malignancies: Tata Memorial experience

Journal of Association of Physicians of India

Volumn 54, Issue JAN., 2006, Pages 29-33

  Biswas, G ^a   Parikh, P M ^a   Nair, R ^a   Bhagwat, R ^a   Bakshi, A ^a   Prabhash, K ^a   Vora, A ^a   Gupta, S ^a   Pai, V R ^a   Menon, H ^a   Sastry, P S R K ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN BCL 2; RITUXIMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; INDIA; MALE; MIDDLE AGED; NONHODGKIN LYMPHOMA; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; INDIA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 29844455819     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000;92:1240-51. ASH 2002.
2. Nair R, Gopal R, Nair CN, Saikia TK, Parikh PM, Joshi SR, Soman CS, Mukaden M, Dinshaw KT, Advani SH. A randomized comparison of the efficacy and toxicity of Epirubicin and Doxorubicin in the treatment of patients with non-hodgkins lymphomas. Cancer 1998;82:2282-8.
3. Nair R, Gopal R, Saikia TK, Soman CS, Joshi SR, Advani SH. MINE therapy for patients with resistant or relapsed non-hodgkins lymphomas. Indian Journal of Medical and Pediatric Oncology 1996;17:90-8.
4. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro : CD55 and CD59 regulate complement mediated cell lysis. Blood 2000;95:3900-8. ASH 2001.
5. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scnad J Immunol 2000;51:634-41.
6. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD 20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3 dependent apoptosis. Blood Cells Mol Dis 2000;26:133-43.
7. Cheson BD, Horning SS, Coiffer B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244 (Erratum, J Clin Oncol 2000, 18:2351) NEJM
8. Cancer Therapy Evaluation Program, Common toxicity criteria, version 2.0, Md.: National Cancer Institute March 1998. NEJM
9. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-76.
10. Czuczman MS, Robin Weaver, Baha Alkuzweny, Judy Berlfein, Grillo-Lopez AJ. Prolonged Clinical and Molecular Remission in patients with low-grade or follicular Non-Hodgkin's lymphoma treated with Rituximab plus CHOP chemotherapy: 9-year follow-up. JCO, 2004;22:1-6.
11. Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as first-line maintenance therapy for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL) (abstract). Blood 2001;98:363a. ASH 2002/48.
12. Thomas DA, O Brien S, Giles FJ, et al. Single agent rituxan in early stage chronic lymphocytic leukemia (CLL) (abstract). Blood 2001; 98:364a. ASH 2002/49.
13. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneus anti- CD52 monoclonal antibody alemtuzumab (Campath- 1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood In press. ASH 2002/43.
14. Bryd JC, Kitada S, Flinn IW, et al. The mechanism of tumour cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002;99:1038-43. ASH 2002/50.
15. Bryd JC, Kitada S, Flivin JW, et al. The mechanism of tumour cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002;99:1038-43. ASH 2002/50.
16. O Brien SM, Kantarijian H, Thomas DA, et al. Rituximab dose escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-79.
17. Byrd JC, Murphy T, Howard RS, et al. Rituximab using the thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic leukemia. J Clin Oncol 2001;19:2153-64.
18. Golay J, Xiao YM, Di Gaetano N, et al. Fludarabine synergises with anti-CD20 monoclonal antibody rituximab in complement mediated cell lysis. Blood 2001;96:339a. Abstract 1463.
19. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19:389-97.
20. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with Diffuse Large B-Cell Lymphoma. N Engl J Med 2002;346:235-42.